Erdheim-Chester组织细胞增生症肾脏受累的临床表型与长期结局
该多中心队列纳入195例Erdheim-Chester病(ECD)患者,147例诊断时存在肾周或输尿管周围受累,其中70例肾积水、16例肾萎缩。肾周受累者诊断时eGFR中位数74 vs 无受累者98 mL/min/1.73 m2。中位随访43个月,肾周受累者5年CKD 3-5期发生率为44% vs 无受累者5%。
要点
- ECD肾周或输尿管周围受累常见,诊断时即可出现肾积水、肾萎缩及eGFR降低。
- 输尿管支架置入常未能恢复肾功能,一线药物治疗对肾脏功能改善亦有限。
- 肾周受累者5年CKD 3-5期发生率为44%,无受累者为5%。
核心结论
- 肾脏受累在ECD中常见,尽管接受有效药物治疗或泌尿外科操作,仍可导致CKD或肾衰竭。
研究设计与样本
- 多中心队列研究,纳入195例连续ECD患者,分析临床特征、影像学表现及长期肾脏结局。
主要发现
- 诊断时147例存在腹膜后肾周或输尿管周围受累,其中70例肾积水(双侧47例)、16例肾萎缩(单侧14例)。
- 60例发现肾血管蒂浸润,31例发现肾动脉狭窄。
- 诊断时eGFR在肾周受累者中位数74 vs 无肾周受累者98 mL/min/1.73 m2。
- 181例接受药物治疗,一线治疗包括干扰素-α(61%)、BRAF抑制剂(17%)、mTOR抑制剂(7%)或其他药物(15%);这些治疗对ECD有效,但罕致肾功能改善(1年内eGFR升高超过25%者不足10%)。
- 中位随访43个月,19%患者死亡,5%发生肾衰竭;肾周受累者5年CKD 3-5期发生率为44% vs 无肾周受累者5%。
关键数值与推荐
- 未调整的晚期CKD及肾衰竭/死亡预测因素包括年龄超过50岁、高血压、BRAFV600E突变及基线eGFR。
- 多变量分析中心血管合并症与晚期CKD相关,年龄超过50岁与肾衰竭/死亡相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Erdheim-Chester disease (ECD) is a rare non-Langerhans cell histiocytosis that frequently infiltrates the peri-kidney space ("hairy kidney" appearance), kidney pelvis and proximal ureters, leading to obstructive uropathy. Here, we analyzed the clinical characteristics, imaging findings and long-term kidney outcome of a large multicenter cohort comprising 195 consecutive patients with ECD. Retroperitoneal peri-kidney or peri-ureteral involvement was detected at diagnosis in 147 patients. Of them, 70 had hydronephrosis (bilateral in 47), and 16 with kidney atrophy (unilateral in 14). Kidney vascular peduncle infiltration was found in 60 patients, and kidney artery stenosis in 31. The estimated glomerular filtration rate (eGFR) at diagnosis was significantly lower in patients with than in those without peri-kidney involvement (median 74 vs. 98 mL/min/1.73 m2). Ureteral stenting often failed to achieve kidney function recovery. A total of 181 patients received medical therapies: first-line treatments included interferon-α (61%), BRAF-inhibitors (17%), mTOR-inhibitors (7%), or other drugs (15%). These therapies were efficacious for ECD but rarely induced kidney function improvement (one-year eGFR increase over 25% in under 10% of patients). After a median of 43 months, 19% of patients died and 5% developed kidney failure. Among patients with peri-kidney involvement, 44% developed chronic kidney disease (CKD) 3-5 at five years vs. 5% of those without. Unadjusted predictors of advanced CKD and kidney failure/death were age over 50 years, hypertension, BRAFV600E mutation, and baseline eGFR. At multivariable analysis, cardiovascular comorbidities were associated with advanced CKD, and age over 50 years with kidney failure/death. Thus, kidney involvement is common in ECD and can lead to CKD or kidney failure despite effective medical therapies or urological procedures.
引用
- Chazal T, Pegoraro F, Manari G, et al. Clinical phenotypes and long-term outcome of kidney involvement in Erdheim-Chester histiocytosis. Kidney Int. 2022. PMID: 36374823. doi:10.1016/j.kint.2022.09.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。